Patents by Inventor Lili Feng

Lili Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110171159
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: October 18, 2010
    Publication date: July 14, 2011
    Applicant: NOVARTIS AG
    Inventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
  • Publication number: 20090163478
    Abstract: The invention relates to salts of 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing such salts and crystalline forms.
    Type: Application
    Filed: May 21, 2007
    Publication date: June 25, 2009
    Inventors: Lili Feng, Xinglong Jiang, Piotr H. Karpinski
  • Publication number: 20090156585
    Abstract: A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.
    Type: Application
    Filed: November 8, 2006
    Publication date: June 18, 2009
    Inventors: Lili Feng, Sven Erik Godtfredsen, Bin Hu, Yugang Liu, Piotr Karpinski, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Thomas J. Blacklock
  • Publication number: 20090131528
    Abstract: The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt.
    Type: Application
    Filed: February 23, 2007
    Publication date: May 21, 2009
    Inventors: Lili Feng, Piotr Karpinski, Raeann Wu
  • Patent number: 7067472
    Abstract: Compositions comprising OB-R agonists and methods of treatment for conditions such as systemic inflammatory response syndrome are provided. One suitable OB-R agonist ligand is recombinant human OB protein, also known as leptin. Also provided are methods and compositions for the treatment of obesity and OB resistance. Assay methods and kits relating to these conditions are also included.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: June 27, 2006
    Assignee: The Scripps Research Institute
    Inventors: Lili Feng, Shizhong Chen, Yiyang Xia
  • Patent number: 5731343
    Abstract: The present invention provides a method of treating an immunopathological disorder having an etiology associated with production of a proinflammatory agent, by administering a compound of the formula: ##STR1## where R1 and R2 are independently H or --COR3; R3 is H, 1-50C alkyl, 1-20C alkoxy, 2-30C alkenyl, 2-30C alkenyloxy, 2-10 alkynyl, 6-14C aryl or aryloxy, a 5-6 membered heterocycle (containing 1-3 N, O and/or S heteroatoms and optionally fused to an aryl group), 3-8C cycloalkyl (optionally fused to aryl) or 5-8C cycloalkenyl; and R4 is a halogen. Examples of such proinflammatory agents include interleukin-1 (IL-1), interleukin-6 (IL-6), interferon-.gamma. (IFN-.gamma.), tumor necrosis factor-.alpha. (TNF-.alpha.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: March 24, 1998
    Assignees: The Scripps Research Institute, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Lili Feng, Daniel Hwang